Comment
Author: Admin | 2025-04-28
Rexulti is a drug owned by Otsuka Pharmaceutical Co Ltd. It is protected by 12 US drug patents filed from 2015 to 2024 out of which none have expired yet. Rexulti's patents will be open to challenges from 10 November, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 12, 2033. Details of Rexulti's patents and their expiration are given in the table below. Drug Patent Number Drug Patent Title Drug Patent Expiry Status These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. USRE48059 Piperazine-substituted benzothiophenes for treatment of mental disorders Dec, 2028 (3 years from now) Active US7888362 Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026 (1 year, 1 month from now) Active These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). US10307419 (Pediatric) Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof Apr, 2033 (8 years from now) Active US10307419 Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof Oct, 2032 (7 years from now) Active USRE48059 (Pediatric) Piperazine-substituted benzothiophenes for treatment of mental disorders Jun, 2029 (4 years from now) Active US8618109 (Pediatric) Piperazine-substituted benzothiophenes for treatment of mental disorders Oct, 2026 (1 year, 7 months from now) Active US7888362 (Pediatric) Piperazine-substituted benzothiophenes for treatment of mental disorders Oct, 2026 (1 year, 7 months from now) Active US8349840 (Pediatric) Piperazine-substituted benzothiophenes for treatment of mental disorders Oct, 2026 (1 year, 7 months from now) Active US9839637 (Pediatric) Piperazine-substituted benzothiophenes for treatment of mental disorders Oct, 2026 (1 year, 7 months from now) Active US8349840 Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026 (1 year, 1 month from now) Active US9839637 Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026 (1 year, 1 month from now) Active US8618109 Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026 (1 year, 1 month from now) Active A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on
Add Comment